Compare Kinder Morgan Inc (KMI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Kinder Morgan Inc trades at $31.6 (market cap $69.90B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Kinder Morgan Inc pays a 3.76% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| KMI | VRTX | |
|---|---|---|
Market Cap | $69.90B | $132.79B |
Sector | Energy | Health |
52-Week High | $34.31 | $529.65 |
52-Week Low | $25.84 | $376.62 |
Enterprise Value | $101.95B | $126.92B |
Dividend Yield | 3.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $30.85, down 1.37% over the past day, with a bearish technical signal from moving averages and oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.37 versus $0.32 expected, and raised full-year guidance. Revenue for 2025 was $16.94 billion, with net income of $3.06 billion and a profit margin of 18.04%. Recent news highlights growth in natural gas infrastructure driven by LNG and power demand, supporting a dividend of $0.30 per share.
KMI presents a mixed outlook; fundamentals are solid with earnings beats and a robust project pipeline, but technical indicators signal near-term caution. Investment opportunities include dividend income and exposure to energy infrastructure growth, while risks involve debt levels and oil price volatility. Analyst consensus is nearly evenly split between buy and hold ratings, reflecting balanced sentiment amid macroeconomic uncertainties.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
